DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading
DSN LINK STABLECARRIER WAVE LOCKORBITAL INDEX HOTSIGNAL CLOCK SYNCLOW NOISE FLOORFRAME BUFFER ONLINE
Loading portal core
2 articles
Ocrelizumab significantly slowed disability progression in a major international Phase III trial of primary progressive multiple sclerosis, including older patients and people with more advanced disease.
The April 2026 *Nature Medicine* editorial doesnāt just call health information importantāit classifies unequal access as a *structural determinant of health*, a category previously reserved for factors like income or pollution.
